[HTML][HTML] Differentiating benign from malignant thyroid tumors by kinase activity profiling and dabrafenib BRAF V600E targeting
R Hilhorst, A van den Berg, P Boender, T van Wezel… - Cancers, 2023 - mdpi.com
Simple Summary Recurrent non-medullary thyroid cancer (NMTC) is difficult to treat and
therapy options are limited. Of the available compounds, serine/threonine kinase (STK) …
therapy options are limited. Of the available compounds, serine/threonine kinase (STK) …
[HTML][HTML] Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting
R Hilhorst, A van den Berg, P Boender, T van Wezel… - Cancers, 2023 - ncbi.nlm.nih.gov
Differentiated non-medullary thyroid cancer (NMTC) can be effectively treated by surgery
followed by radioactive iodide therapy. However, a small subset of patients shows …
followed by radioactive iodide therapy. However, a small subset of patients shows …
Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting
R Hilhorst, A van den Berg, P Boender… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Differentiated non-medullary thyroid cancer (NMTC) can be effectively treated by surgery
followed by radioactive iodide therapy. However, a small subset of patients shows …
followed by radioactive iodide therapy. However, a small subset of patients shows …
Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting.
R Hilhorst, A van den Berg, P Boender… - …, 2023 - search.ebscohost.com
Abstract Simple Summary: Recurrent non-medullary thyroid cancer (NMTC) is difficult to
treat and therapy options are limited. Of the available compounds, serine/threonine kinase …
treat and therapy options are limited. Of the available compounds, serine/threonine kinase …
Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting
R Hilhorst, A van den Berg, P Boender, T van Wezel… - Cancers, 2023 - europepmc.org
Differentiated non-medullary thyroid cancer (NMTC) can be effectively treated by surgery
followed by radioactive iodide therapy. However, a small subset of patients shows …
followed by radioactive iodide therapy. However, a small subset of patients shows …
Differentiating benign from malignant thyroid tumors by kinase activity profiling and dabrafenib BRAF V600E targeting
R Hilhorst, A Berg, P Boender, T Wezel… - …, 2023 - scholarlypublications …
Differentiated non-medullary thyroid cancer (NMTC) can be effectively treated by surgery
followed by radioactive iodide therapy. However, a small subset of patients shows …
followed by radioactive iodide therapy. However, a small subset of patients shows …
Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting
R Hilhorst, A van den Berg, P Boender, T van Wezel… - …, 2023 - search.proquest.com
Differentiated non-medullary thyroid cancer (NMTC) can be effectively treated by surgery
followed by radioactive iodide therapy. However, a small subset of patients shows …
followed by radioactive iodide therapy. However, a small subset of patients shows …
Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting.
R Hilhorst, A van den Berg, P Boender, T van Wezel… - Cancers, 2023 - europepmc.org
Differentiated non-medullary thyroid cancer (NMTC) can be effectively treated by surgery
followed by radioactive iodide therapy. However, a small subset of patients shows …
followed by radioactive iodide therapy. However, a small subset of patients shows …